Building a clinical trial involves a host of logistical and manual operations as part of the overall process. Leveraging technology available today, Syneos Health has been able to modernize their approach shortening their clinical study build times by 50 percent. Automation is the key, shortening time consuming manual operations as part of the electronic data capture (EDC) process. Syneos is also implementing new solutions to aggregate and clean trial data more efficiently and provide analysis-ready data at all times.

Join the featured speaker to hear lessons learned about cutting clinical study build times by 50 percent.

Keywords:

Speaker

Trevor Griffiths, Sr. Director, Clinical Data Management, Syneos Health

Trevor Griffiths, as a senior leader within Syneos’ Biometrics group, is responsible for overseeing Biometrics partnerships with their strategic partners. Griffiths has been with Syneos Health for over 24 years serving in many leadership positions within data management, programming, biostatistics and medical writing. He has a strong technical background in operational delivery and has worked across the majority of industry leading systems and rolled out & implemented a multitude of service solutions for Syneos’ strategic partners. Griffiths also led the implementation of Veeva CDMS within Syneos Health.

Message Presenter

Who Should Attend?

This webinar will appeal to senior professionals in the areas of:

Clinical Data Management
Data Management
Clinical Science
Clinical Development
Biometrics
Biostatistics
Informatics

What You Will Learn

Attendees will:

Learn how to shorten clinical trial build times
Learn how to modernize the next clinical trial build
Learn how new electronic data capture (EDC) automation and leveraging data aggregation and cleaning tools can streamline manual processes

Xtalks Partner

Veeva

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,100 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit www.veeva.com.